IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Study Identifier
IMGN0301
CT.gov Identifier
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact
Study Complete

Study Details

Medical Condition
  • Blood Cancer - Non-Hodgkin's Lymphoma (General)
  • Blood Cancer - Chronic Lymphocytic Leukemia (CLL)
  • Study Drug
  • IMGN529
  • Phase
    Phase 1
    Sex
    Female & Male
    Age
    18+ years

    Protocol Summary

    The purpose of this study is to test the safety and tolerability of IMGN529 in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL).

    Study Locations

    Location
    Status
    Location
    Dana Farber Cancer Institute
    Boston, Massachusetts, United States, 02215
    Status
    Not applicable
    Location
    Memorial Sloan-Kettering Cancer Center
    New York, New York, United States, 10021
    Status
    Not applicable
    Location
    Ohio State University
    Columbus, Ohio, United States, 43210
    Status
    Not applicable
    Location
    Sarah Cannon Research Institute
    Nashville, Tennessee, United States, 37203
    Status
    Not applicable
    Location
    CTRC at UTHSCSA
    San Antonio, Texas, United States, 78229
    Status
    Not applicable
    Location
    Medical College of Wisconsin
    Milwaukee, Wisconsin, United States, 53226
    Status
    Not applicable
    Showing {first} - {last} of {total} Results